Published by Scientific Scholar on behalf of Molecular Oncology Society and Immuno Oncology Leadership Network.
ISSN (Online): 2456-3994
ISSN (Print): 2836-3779
Focus and Scope | Audience | Review Process | Editorial Team | About the Editors | Facts About the Journal | Benefits | Abstracting and Indexing Information | Journal Ethics | Plagiarism Policy | Archival Policy | Open Access Publication and Creative Commons Licensing | Ahead of Print Policy | Advertisements | Subscription Information | Publisher
International Journal of Molecular and Immuno Oncology (IJMIO) is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Molecular Biological and Immunological aspects of Oncology. The journal is owned by the Alms Tech LLP and published by the Scientific Scholar.
IJMIO is a peer-reviewed 3 (three) issues journal that is published both online and in print jointly by Molecular Oncology Society and Immuno Oncology Leadership Network. It is published by Scientific Scholar. The journal’s full text is available online at (https://ijmio.com). IJMIO is an Open Access journal, and online access to full text articles is provided at no charge for non-commercial use. The journal does not charge for submission or acceptance of manuscripts.
IJMIO employs the highest standards in publishing, backed by the years of experience of the Molecular Oncology Society and Immuno Oncology Leadership Network. The journal follows stringent peer-review and editorial policies that allow for the selection of high-quality work to be published. All manuscripts are evaluated by peer-review for their quality of science (including novelty, technical methodology, and integrity). The editorial policy is to require all authors to disclose any relevant financial associations and declare that financial interests have not influenced the content of the manuscript being published. This is in keeping with the high ethical standards we strive to ensure for all work published in IJMIO.
International Journal of Molecular and Immuno Oncology (IJMIO) is dedicated to providing a platform for highlighting novel and relevant research and exchange of knowledge at the crossroads of bench and bedside research. The goal is to provide information in an understandable format for clinicians and keep up with the fast-paced developments in Molecular Biology and Immunology related to Oncology.
Our audience includes Molecular Oncologists, Immunologists, medical professionals and students.
IJMIO has a highly rigorous double-blinded peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts of interest, affiliations and financial disclosures such that the published content is not biased.
In-house submissions that contain the work of any editorial board member, are not allowed to be reviewed by that editorial board member and all decisions regarding this manuscript are made by an independent editor. In addition, these manuscripts are reviewed by the two external reviewers. This is also disclosed in the published manuscript under the section of Conflict of Interest.
The editorial board comprises a panel of international experts in Molecular and Immuno Oncology from various countries to provide their expertise and guidance to the Editor-In-Chief in maintaining the clarity of content and focus of the journal’s purpose.
Dr. Purvish M. Parikh MD, DNB, FICP, PHD, ECMO, CPI, MBA
Dr. Purvish M. Parikh is
Dr. Randeep Singh MD, DM, ECMO, FCCP
Dr. Singh currently is working as a Senior consultant and unit head at Artemis Hospital, Gurugram. He also owns the ONCOMED clinic at Hauz Khas, Delhi. He has been trained extensively in the management of cancer patients at the prestigious Tata Memorial Hospital (TMH), Mumbai. He did his Doctorate (DM: Medical Oncology) from Tata Memorial Hospital, Mumbai and then worked as a consultant at TMH, Mumbai with the solid tumor-working group before joining the Max group of hospitals. He worked as a Consultant with Max Healthcare for five years. Thereafter he was heading the Department of Medical Oncology at HCG cancer center, Delhi before joining ARTEMIS Hospitals, Gurgaon. His key area of interest is lung cancer, gastrointestinal and breast cancer.
Dr. Singh has more than 40 publications in national and international journals of high impact factor. He has also attended and presented various scientific papers in national and international journals. He is a distinguished faculty at various national and international conferences. He currently serves as Joint Secretary at Indian Society Medical & Pediatric Oncology (ISMPO). He is a co-founder member of the International CME organization and an executive member of various national organizations such as ICON (Indian Co-Operative Oncology Network), ISMPO (Indian Society of Medical & Pediatric Oncology), Delhi Oncology Forum. He is also associated with international societies such as ESMO (European Society of Medical Oncology) & ASCO (American Society of Clinical Oncology).
Scope of the journal
IJMIO is a peer-reviewed journal that highlights the latest developments, approaches, and discoveries in basic, clinical and translational oncology. The journal reviews and accepts original clinical and laboratory-based research manuscripts as well as invited reviews focused on molecular biological and immunological aspects of oncology. Articles addressing contemporary advances and challenges faced in molecular and immune-oncology in developing nations are also strongly encouraged.
Key areas covered by the journal include
This journal publishes manuscripts in the following sections
All manuscripts submitted through all the sections are peer-reviewed prior to acceptance. It is a peer-reviewed international journal with a double-blind review process. Its frequency of publication is 3 (three) issues per year. The Journal is published both online and in print.
A manuscript published in the journal can be read and downloaded by readers all over the world without any charges or fees. The author retains the copyright of the manuscript and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.
The journal is registered with the following abstracting partners:Google Scholar, ProQuest, ReadCube, CrossRef, Portico
International Journal of Molecular and Immuno Oncology is committed to meeting and upholding ethical guidelines at all stages of the publication process. We follow the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE), and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines Section.
We use PORTICO for our third-party repository for all articles published with us. All our manuscripts are assigned a DOI number from CROSSREF, and we are members of Crossref https://crossref.org
International Journal of Molecular and Immuno Oncology is an open-access journal, and manuscripts published are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0), which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. IJMIO has a policy that changes will not be made after the publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place (https://scientificscholar.com/adv-policies/) to ensure the integrity of the journal and its content are not biased or influenced by the advertisement.
“Pop-up” and “Banner” advertisement appears at a fixed location on the page and does not interfere with the reading/display of the manuscript in any form. (https://ijmio.com/advertise/)
All advertisements are approved in consultation with Editor-In-Chief/the Editorial Board.
Advertisers submit their advertisements without prior information of the journal content to be published.
Copies are provided free to members of the journal’s institution.
For non-members, please log on to https://scientificscholar.com/buy-subscriptions.
Scientific Scholar LLC (scientificscholar.com) is a well-respected medical publisher that fully supports open access publishing models, Subscription and Society based journal models through its own in-house peer-review management system – EditorialAssist (journalmanagement.org). The head office of Scientific Scholar is in Rochester, NY, USA and has a subsidiary arm in India.
The mission of the Scientific Scholar is “Share, Learn and Improve”.